Evidence map›Paper›PMID 32728988›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2020

The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era.

Yawen Zheng, Yilun Sun, Hongyan Yang, Jie Liu, Ligang Xing, Yuping Sun

Abstract read
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Low income and health literacy: a systematic scoping review.Archives of public health = Archives belges de sante publique · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yawen ZhengDepartment of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong First Medical University, No. 105, Jie Fang Road, Jinan, 250012, Shandong, People's Republic of China.
Yilun SunDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Hongyan YangDepartment of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong First Medical University, No. 105, Jie Fang Road, Jinan, 250012, Shandong, People's Republic of China.
Jie LiuDepartment of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong First Medical University, No. 105, Jie Fang Road, Jinan, 250012, Shandong, People's Republic of China.
Ligang XingDepartment of Radiation Oncology, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Jinan, 250117, Shandong, China. xinglg@medmail.com.cn.ORCID http://orcid.org/0000-0002-9146-3048
Yuping SunDepartment of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Shandong First Medical University, No. 105, Jie Fang Road, Jinan, 250012, Shandong, People's Republic of China. 13370582181@163.com.

Funding

Jinan Science and Technology Bureau 201907122
6 · The paper itself

Abstract

purposeThe influence of socioeconomic status on metastatic clear cell renal cell carcinoma (RCC) in the target therapy era is still unknown. This study aimed to assess the role of income disparities on prognosis of mRCC in the targeted therapy era. PATIENTS AND

methodsData of patients with mRCC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Median household income (MHI) was used to represent patients' socioeconomic status, and its role on overall survival (OS) and cancer-specific survival (CSS) was evaluated.

resultsA total of 3791 patients with clear cell mRCC diagnosed between 2010 and 2015 were enrolled in cohort one. There was an obvious imbalance of race and insurance status in patients with difference MHI. Compared with patients in the poorest quartile 1 (Q1), those in the wealthiest Q4 had a 4-month prolonged OS (P < 0.01) and a 5-month prolonged CSS (P < 0.01), and those in Q3 and Q4 had significantly lower death risk. High income decreased cumulative cancer-specific mortality rates, and potentially favored survival in most subgroups. 6619 patients diagnosed between 2004 and 2015 were included in cohort two. We found that only those with Q4 income achieved a prolonged survival with statistical significance by comparing between patients diagnosed in 2004-2009 and 2010-2015.

conclusionIn the targeted therapy era, there were survival gaps of mRCC between patients with low- and high-income. Measures should be taken to develop a comprehensive and financially sustainable plan of cancer treatment for greater equity.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCohort StudiesHumansIncomeMolecular Targeted TherapyIncome disparitiesMetastatic clear cell renal cell carcinomaSurvival gapsTargeted therapy era

Identifiers

PMID32728988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.